26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Burden of Opioid-Related Mortality in the United States

      research-article
      , PhD 1 , 2 , , , PharmD, PhD 1 , , PharmD, MA, MPH 1 , 2 , , MSc 2 , , MD, PhD 2 , 3
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What has been the burden of opioid-related deaths in the United States over a recent 15-year period?

          Findings

          In this serial cross-sectional study, we found that the percentage of all deaths attributable to opioids increased 292% (from 0.4% to 1.5%) between 2001 and 2016, resulting in approximately 1.68 million person-years of life lost in 2016 alone (5.2 per 1000 population). The burden was particularly high among adults aged 24 to 35 years; in 2016, 20% of deaths in this age group involved opioids.

          Meaning

          Premature death from opioids imposes an enormous and growing public health burden across the United States.

          Abstract

          This population epidemiology study uses Centers for Disease Control and Prevention (CDC) mortality data to characterize trends in opioid-related deaths and estimate years of life lost due to opioids in the United States between 2001 and 2016.

          Abstract

          Importance

          Opioid prescribing and overdose are leading public health problems in North America, yet the precise public health burden has not been quantified.

          Objective

          To examine the burden of opioid-related mortality across the United States over time.

          Design, Setting, and Participants

          This study used a serial cross-sectional design in which cross sections were examined at different time points to investigate deaths from opioid-related causes in the United States between January 1, 2001, and December 31, 2016.

          Main Outcomes and Measures

          Opioid-related deaths, defined as those in which a prescription or illicit opioid contributed substantially to an individual’s cause of death as determined by death certificates. We compared the percentage of deaths attributable to opioids and the associated person-years of life lost by age group.

          Results

          Between 2001 and 2016, the number of opioid-related deaths in the United States increased by 345%, from 9489 to 42 245 deaths (33.3 to 130.7 deaths per million population). By 2016, men accounted for 67.5% of all opioid-related deaths, and the median (interquartile range) age at death was 40 (30-52) years. The percentage of deaths attributable to opioids increased in a similar fashion. In 2001, 0.4% of deaths (1 in 255) were opioid related, rising to 1.5% of deaths (1 in 65) by 2016, an increase of 292%. This burden was highest among adults aged 24 to 35 years. In this age group, 20.0% of deaths were attributable to opioids in 2016. Among those aged 15 to 24 years, 12.4% of deaths were attributable to opioids in 2016. Overall, opioid-related deaths resulted in 1 681 359 years of life lost (5.2 per 1000 population) in the United States in 2016, most of which (1 125 711 years of life lost) were among men. Adults aged 25 to 34 years had 12.9 years of life lost per 1000 population, and those aged 35 to 44 years had 9.9 years of life lost per 1000 population.

          Conclusions and Relevance

          Premature death from opioid-related causes imposes an enormous public health burden across the United States. The recent increase in deaths attributable to opioids among those aged 15 to 34 years highlights a need for targeted programs and policies that focus on improved addiction care and harm reduction measures in this high-risk population.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.

          (2011)
          Overdose deaths involving opioid pain relievers (OPR), also known as opioid analgesics, have increased and now exceed deaths involving heroin and cocaine combined. This report describes the use and abuse of OPR by state. CDC analyzed rates of fatal OPR overdoses, nonmedical use, sales, and treatment admissions. In 2008, drug overdoses in the United States caused 36,450 deaths. OPR were involved in 14,800 deaths (73.8%) of the 20,044 prescription drug overdose deaths. Death rates varied fivefold by state. States with lower death rates had lower rates of nonmedical use of OPR and OPR sales. During 1999--2008, overdose death rates, sales, and substance abuse treatment admissions related to OPR all increased substantially. The epidemic of overdoses of OPR has continued to worsen. Wide variation among states in the nonmedical use of OPR and overdose rates cannot be explained by underlying demographic differences in state populations but is related to wide variations in OPR prescribing. Health-care providers should only use OPRs in carefully screened and monitored patients when non-OPR treatments are insufficient to manage pain. Insurers and prescription drug monitoring programs can identify and take action to reduce both inappropriate and illegal prescribing. Third-party payers can limit reimbursement in ways that reduce inappropriate prescribing, discourage efforts to obtain OPR from multiple health-care providers, and improve clinical care. Changes in state laws that focus on the prescribing practices of health-care providers might reduce prescription drug abuse and overdoses while still allowing safe and effective pain treatment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study.

            To estimate the prevalence and burden of disease attributable to opioid dependence globally, regionally and at country level. Multiple search strategies: (i) peer-reviewed literature searches; (ii) systematic searches of online databases; (iii) internet searches; (iv) consultation and feedback from experts. Culling and data extraction followed protocols. DisMod-MR, the latest version of the generic disease modelling system, a Bayesian meta-regression tool, imputed prevalence by age, year and sex for 187 countries and 21 regions. Disability weight for opioid dependence was estimated through population surveys and multiplied by prevalence data to calculate the years of life lived with disability (YLDs). Opioid dependence premature mortality was computed as years of life lost (YLLs) and summed with YLDs to calculate disability-adjusted life years (DALYs). There were 15.5 million opioid-dependent people globally in 2010 [0.22%, 95% uncertainty interval (UI) = 0.20-0.25%]. Age-standardized prevalence was higher in males (0.30%, 95% UI = 0.27-0.35%) than females (0.14%, 95% UI = 0.12-0.16%), and peaked at 25-29 years. Prevalence was higher than the global pooled prevalence in Australasia (0.46%, 95% UI = 0.41-0.53%), western Europe (0.35%, 95% UI = 0.32-0.39) and North America (0.30%, 95% UI = 0.25-0.36). Opioid dependence was estimated to account for 9.2 million DALYs globally (0.37% of global DALYs) in 2010, a 73% increase on DALYs estimated in 1990. Regions with the highest opioid dependence DALY rates were North America (292.1 per 100,000), eastern Europe (288.4 per 100,000), Australasia (278.6 per 100,000) and southern sub-Saharan Africa (263.5 per 100,000). The contribution of YLLs to opioid dependence burden was particularly high in North America, eastern Europe and southern sub-Saharan Africa. Opioid dependence is a substantial contributor to the global disease burden; its contribution to premature mortality (relative to prevalence) varies geographically, with North America, eastern Europe and southern sub-Saharan Africa most strongly affected. © 2014 Society for the Study of Addiction.
              Bookmark
              • Record: found
              • Abstract: not found
              • Report: not found

              Latest trends in opioid-related deaths in Ontario

                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                1 June 2018
                June 2018
                1 June 2018
                : 1
                : 2
                : e180217
                Affiliations
                [1 ]Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ontario, Canada
                [2 ]Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
                [3 ]Sunnybrook Research Institute, Toronto, Ontario, Canada
                Author notes
                Article Information
                Accepted for Publication: March 14, 2018.
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Gomes T et al. JAMA Network Open.
                Corresponding Author: Tara Gomes, PhD, St. Michael’s Hospital, 30 Bond St, Toronto, ON M5B 1W8, Canada ( gomest@ 123456smh.ca ).
                Author Contributions: Dr Gomes had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: All authors.
                Acquisition, analysis, or interpretation of data: Gomes, Tadrous, Mamdani, Paterson.
                Drafting of the manuscript: Gomes.
                Critical revision of the manuscript for important intellectual content: Tadrous, Mamdani, Paterson, Juurlink.
                Statistical analysis: Gomes, Mamdani.
                Obtained funding: Gomes.
                Administrative, technical, or material support: Gomes.
                Supervision: Mamdani, Juurlink.
                Conflict of Interest Disclosures: Dr Gomes reported grants from the Canadian Institutes of Health Research during the conduct of the study and grants from the Ontario Ministry of Health and Long-Term Care outside the submitted work. Dr Mamdani reported personal fees from Novo Nordisk, Allergan, Celgene, and EMD Serono outside the submitted work. Dr Juurlink reported unpaid membership in Physicians for Responsible Opioid Prescribing (PROP) and the American College of Medical Toxicology.
                Funding/Support: This study was funded by grant 153070 from the Canadian Institutes of Health Research. This study was also supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care.
                Role of the Funder/Sponsor: The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences, the Strategy for Patient-Oriented Research Unit of the Canadian Institutes of Health Research, or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred.
                Article
                zoi180031
                10.1001/jamanetworkopen.2018.0217
                6324425
                30646062
                7028fa99-964a-477e-b19d-93117f146043
                Copyright 2018 Gomes T et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 22 February 2018
                : 13 March 2018
                : 14 March 2018
                Categories
                Research
                Original Investigation
                Featured
                Online Only
                Substance Use and Addiction

                Comments

                Comment on this article